key: cord-1003431-cj5pjtf1
authors: Edara, Venkata Viswanadh; Norwood, Carson; Floyd, Katharine; Lai, Lilin; Davis-Gardner, Meredith E.; Hudson, William H.; Mantus, Grace; Nyhoff, Lindsay E.; Adelman, Max W.; Fineman, Rebecca; Patel, Shivan; Byram, Rebecca; Gomes, Dumingu Nipuni; Michael, Garett; Abdullahi, Hayatu; Beydoun, Nour; Panganiban, Bernadine; McNair, Nina; Hellmeister, Kieffer; Pitts, Jamila; Winters, Joy; Kleinhenz, Jennifer; Usher, Jacob; O’Keefe, James B.; Piantadosi, Anne; Waggoner, Jesse J.; Babiker, Ahmed; Stephens, David S.; Anderson, Evan J.; Edupuganti, Srilatha; Rouphael, Nadine; Ahmed, Rafi; Wrammert, Jens; Suthar, Mehul S.
title: Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant
date: 2021-02-22
journal: bioRxiv
DOI: 10.1101/2021.02.20.432046
sha: 71bde3e1bd51470c1ebba3846e1ea8d2f7537788
doc_id: 1003431
cord_uid: cj5pjtf1

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies to neutralize these variants. We compared antibody binding and live virus neutralization of sera from naturally infected and spike mRNA vaccinated individuals against a circulating SARS-CoV-2 B.1 variant and the emerging B.1.351 variant. In acutely-infected (5-19 days post-symptom onset), convalescent COVID-19 individuals (through 8 months post-symptom onset) and mRNA-1273 vaccinated individuals (day 14 post-second dose), we observed an average 4.3-fold reduction in antibody titers to the B.1.351-derived receptor binding domain of the spike protein and an average 3.5-fold reduction in neutralizing antibody titers to the SARS-CoV-2 B.1.351 variant as compared to the B.1 variant (spike D614G). However, most acute and convalescent sera from infected and all vaccinated individuals neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective immunity is retained against COVID-19.

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns 29 about the efficacy of infection-or vaccine-induced antibodies to neutralize these variants. We Regression analysis showed a significant correlation between B.1-lineage RBD-specific IgG and 129 neutralization titers against the B.1 variant (R 2 = 0.5; p<0.0001; Fig 1K) The immune correlates of protection against SARS-CoV-2 are not yet known. We and others 162 have previously shown, IgG antibody responses to the RBD can serve as a surrogate of viral 163 neutralization in infected individuals (Greaney et al., 2021; Piccoli et al., 2020; Suthar et al., 164 2020 (Edara et al., 2021; Johnson et al., 2021; Rathnasinghe 169 et al., 2021; Shen et al., 2021; Wu et al., 2021) . The substitution at position E484, located in the 170 receptor-binding ridge epitope (Greaney et al., 2021) , shows resistance to the neutralization of 171 convalescent human sera. Single point mutant pseudoviruses, chimeric viruses, or recombinant 172 infectious clone-derived SARS-CoV-2 have demonstrated that this mutation displays resistance 173 to neutralization by infection-and vaccine-induced antibodies (Johnson et al., 2021; Liu et al., 174 2021; Shen et al., 2021; Xie et al., 2021) . This suggests that a majority of individuals develop 175 antibodies that target this region within the RBD. However, it is still unclear whether this 176 mutation also impacts viral fitness, pathogenesis or transmission. vaccination. Another limitation is that the B.1.351 virus that we used in our study contains two 194 substitutions within the spike protein that were not reported in the reference sequence deposited 195 into GISAID (EPI_ISL_678615). One of these is a substitution of a Q677H, which has now been 196 reported in multiple lineages of circulating variants of SARS-CoV-2 in the US population as early 197 as mid-August 2020 (Hodcroft et al., 2021) . The other is a substitution (R682W) within the furin 198 cleavage motif (PRRAR) located between the S1/S2 regions of the spike protein. EHC-083E (herein referred to as the B.1 variant) was derived from a residual nasopharyngeal 322 swab collected from an Emory Healthcare patient in March 2020, as part of a study approved by 323 the institutional review board at Emory University. As described previously (Babiker et al., 324 2020 FRNT assays were performed as previously described . Briefly, 375 samples were diluted at 3-fold in 8 serial dilutions using DMEM (VWR, #45000-304) in 376 duplicates with an initial dilution of 1:10 in a total volume of 60 μl. Serially diluted samples were 377 incubated with an equal volume of SARS-CoV-2 (100-200 foci per well) at 37 o C for 1 hour in a 378 round-bottomed 96-well culture plate. The antibody-virus mixture was then added to Vero cells 379 and incubated at 37 o C for 1 hour. Post-incubation, the antibody-virus mixture was removed and 380 100 µl of prewarmed 0.85% methylcellulose (Sigma-Aldrich, #M0512-250G) overlay was added 381 to each well. Plates were incubated at 37 o C for 24 hours. After 24 hours, methylcellulose 382 overlay was removed, and cells were washed three times with PBS. Cells were then fixed with 383 2% paraformaldehyde in PBS (Electron Microscopy Sciences) for 30 minutes. Following fixation, 384 plates were washed twice with PBS and 100 µl of permeabilization buffer (0.1% BSA [VWR, 385 #0332], Saponin [Sigma, 47036-250G-F] in PBS), was added to the fixed Vero cells for 20 386 minutes. Cells were incubated with an anti-SARS-CoV spike primary antibody directly 387 conjugated to biotin (CR3022-biotin) for 1 hour at room temperature. Next, the cells were 388 washed three times in PBS and avidin-HRP was added for 1 hour at room temperature followed 389 by three washes in PBS. Foci were visualized using TrueBlue HRP substrate (KPL, # 5510-390 0050) and imaged on an ELISPOT reader (CTL). 391 392

Antibody neutralization was quantified by counting the number of foci for each sample using the 394 Viridot program (Katzelnick et al., 2018) . The neutralization titers were calculated as follows: 1 -395 (ratio of the mean number of foci in the presence of sera and foci at the highest dilution of 396 respective sera sample). Each specimen was tested in duplicate. The FRNT-50 titers were 397 interpolated using a 4-parameter nonlinear regression in GraphPad Prism 8.4.3. Samples that 398 do not neutralize at the limit of detection at 50% are plotted at 15 and was used for geometric 399 mean calculations. The SARS-CoV-2 Spike structure was visualized with PyMOL (Schrödinger, 400

Inc.). 401 402 403

Longitudinal analysis of 406 humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-407 symptom onset

Safety and 410 Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Metagenomic Sequencing To Detect Respiratory Viruses in Persons 414 under Investigation for COVID-19

Immunological memory to SARS-CoV-2 assessed for up to 417 8 months after infection

Infection and mRNA-1273 vaccine antibodies 420 neutralize SARS-CoV-2 UK variant. medRxiv

D614G Mutation Alters SARS-CoV-2 Spike 423

Conformation and Enhances Protease Cleavage at the S1/S2 Junction

Complete Mapping of Mutations to the 426 SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Emergence in late 2020 of 430 multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677. 431 medRxiv

An mRNA 434 Vaccine against SARS-CoV-2 -Preliminary Report

Loss of furin cleavage site attenuates SARS-438 CoV-2 pathogenesis

Viridot: An automated virus 441 plaque (immunofocus) counter for the measurement of serological neutralizing responses with 442 application to dengue virus

Identification of SARS-CoV-2 spike mutations 445 that attenuate monoclonal and serum antibody neutralization

SARS-CoV-2 D614G spike mutation increases entry efficiency with 448 enhanced ACE2-binding affinity

Mapping Neutralizing

Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-452 Guided High-Resolution Serology

Spike mutation D614G alters SARS-CoV-2 455 fitness

Stable 458 neutralizing antibody levels six months after mild and severe COVID-19 episode

The N501Y mutation in SARS-CoV-2 spike 461 leads to morbidity in obese and aged mice and is neutralized by convalescent and post-462 vaccination human sera. medRxiv

Antibody potency, effector function, 465 and combinations in protection and therapy for SARS-CoV-2 infection in vivo

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing 469 antibodies elicited by ancestral Spike vaccines

Persistence of SARS-CoV-2 specific 472

T-cell responses in convalescent COVID-19 patients 6-8 months after the infection

Neutralizing and protective human 476 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Rapid Generation of 480 Neutralizing Antibody Responses in COVID-19 Patients

Emergence and rapid spread of a new severe 483 acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike 484 mutations in South Africa

Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

SARS-CoV-2 495 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Durability of 499 Responses after SARS-CoV-2 mRNA-1273 Vaccination

Human neutralizing antibodies against SARS-CoV-2 require 503 intact Fc effector functions and monocytes for optimal therapeutic protection. bioRxiv

Serum Neutralizing Activity Elicited by 507 mRNA-1273 Vaccine -Preliminary Report

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and 510 N501Y variants by BNT162b2 vaccine-elicited sera. bioRxiv